News

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Catch up on this week's highlights in retina.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa.

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

Vonaprument has received fast track designation from the US Food and Drug Administration.

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California